Journal article
Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial
Abstract
CONTEXT: Despite many therapeutic advances, mortality in patients with acute ST-segment elevation myocardial infarction (STEMI) remains high. The role of additional antithrombotic agents is unclear, especially among patients not receiving reperfusion therapy.
OBJECTIVE: To evaluate the effect of fondaparinux, a factor Xa inhibitor, when initiated early and given for up to 8 days vs usual care (placebo in those in whom unfractionated heparin …
Authors
Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJG; Bassand J-P; Wallentin L
Journal
JAMA: The Journal of the American Medical Association, Vol. 295, No. 13, pp. 1519–1530
Publisher
American Medical Association (AMA)
Publication Date
April 5, 2006
DOI
10.1001/jama.295.13.joc60038
ISSN
0098-7484